Singapore markets closed
Straits Times Index
3,313.48 +8.49 (+0.26%) Nikkei
38,787.38 -132.88 (-0.34%) Hang Seng
19,553.61 +177.08 (+0.91%) FTSE 100
8,420.26 -18.39 (-0.22%) Bitcoin USD
66,561.84 +1,572.96 (+2.42%) CMC Crypto 200
1,359.01 -14.84 (-1.08%)
GILD May 2024 65.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:02PM EDT. Market open.
| Previous close | 2.8600 |
| Open | 2.2900 |
| Bid | 2.4700 |
| Ask | 2.6000 |
| Strike | 65.00 |
| Expiry date | 2024-05-17 |
| Day's range | 2.2900 - 2.8400 |
| Contract range | N/A |
| Volume | |
| Open interest | 667 |
Business WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
Yahoo FinanceOne stock is dragging down the S&P 500's earnings growth
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
ZacksGilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
© 2024 Yahoo. All rights reserved.